Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) Latest Company News

Aug 7, 2026, 11:38 UTC
Fosun Pharma's controlled subsidiary Fosun Pharma (Xuzhou) Co., Ltd. obtained registration approval from the National Medical Products Administration for its levalbuterol hydrochloride nebulized inhalation solution, with the approved indication being the treatment or prevention of related bronchospasm in adults and children over 6 years old.
Source:
- finance.sina.cn
Aug 7, 2026, 11:38 UTC
Fosun Pharma's controlling subsidiary Shanghai Zhaohui Pharmaceutical's dobutamine hydrochloride injection received registration approval from the National Medical Products Administration for treating heart failure.
Source:
- finance.sina.cn
- aastocks.com
Aug 3, 2026, 08:19 UTC
Fosun Pharma's controlled subsidiary Suzhou Erye Pharmaceutical received NMPA registration approval for its compound polyethylene glycol (3350) electrolyte powder, indicated for chronic constipation in children aged 1-11 and fecal impaction in children aged 5-11.
Source:
- finance.sina.cn
Aug 3, 2026, 08:19 UTC
Fosun Pharma's controlling subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. obtained registration approval from the National Medical Products Administration for Empagliflozin and Metformin Hydrochloride Extended-Release Tablets (III), indicated to improve glycemic control in adult patients with type 2 diabetes receiving empagliflozin and metformin hydrochloride treatment.
Source:
- finance.sina.cn
Jul 31, 2026, 08:34 UTC
Fosun Pharma's controlling subsidiary Henlius received approval from the National Medical Products Administration to conduct clinical trials of HLX43 injection combined with bevacizumab, with or without chemotherapy, for advanced/metastatic solid tumors.
Source:
Jul 24, 2026, 08:23 UTC
Fosun Pharma's subsidiary Fosun Wanbang received approval from the National Medical Products Administration to conduct a clinical trial for DM1001 to treat Parkinson's disease.
Source:
- finance.sina.cn
Jul 10, 2026, 08:35 UTC
Fosun Pharma's subsidiary Henlius received NMPA approval to conduct a Phase I clinical trial of HLX37 combined with HLX43 for advanced/metastatic solid tumors.
Source:

← PreviousPage 2

600196.SH

Fosun Pharma's controlling subsidiary Shanghai Zhaohui Pharmaceutical's dobutamine hydrochloride injection received registration approval from the National Medical Products Administration for treating heart failure.

Fosun Pharma's controlled subsidiary Suzhou Erye Pharmaceutical received NMPA registration approval for its compound polyethylene glycol (3350) electrolyte powder, indicated for chronic constipation in children aged 1-11 and fecal impaction in children aged 5-11.

Fosun Pharma's controlling subsidiary Henlius received approval from the National Medical Products Administration to conduct clinical trials of HLX43 injection combined with bevacizumab, with or without chemotherapy, for advanced/metastatic solid tumors.

Fosun Pharma's subsidiary Fosun Wanbang received approval from the National Medical Products Administration to conduct a clinical trial for DM1001 to treat Parkinson's disease.

Fosun Pharma's subsidiary Henlius received NMPA approval to conduct a Phase I clinical trial of HLX37 combined with HLX43 for advanced/metastatic solid tumors.